CN113134025A - Application of broccoli extract in preventing and treating leukopenia - Google Patents
Application of broccoli extract in preventing and treating leukopenia Download PDFInfo
- Publication number
- CN113134025A CN113134025A CN202110433627.6A CN202110433627A CN113134025A CN 113134025 A CN113134025 A CN 113134025A CN 202110433627 A CN202110433627 A CN 202110433627A CN 113134025 A CN113134025 A CN 113134025A
- Authority
- CN
- China
- Prior art keywords
- broccoli
- broccoli extract
- extract
- extract according
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 title claims abstract description 78
- 240000003259 Brassica oleracea var. botrytis Species 0.000 title claims abstract description 77
- 235000017647 Brassica oleracea var italica Nutrition 0.000 title claims abstract description 73
- 239000000284 extract Substances 0.000 title claims abstract description 41
- 201000002364 leukopenia Diseases 0.000 title claims abstract description 14
- 231100001022 leukopenia Toxicity 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 108090000790 Enzymes Proteins 0.000 claims abstract description 7
- 102000004190 Enzymes Human genes 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 244000308180 Brassica oleracea var. italica Species 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 238000001035 drying Methods 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000000265 leukocyte Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 235000006533 astragalus Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 241001061264 Astragalus Species 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 241000227653 Lycopersicon Species 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 125000004383 glucosinolate group Chemical group 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000011303 Brassica alboglabra Nutrition 0.000 description 1
- 235000011302 Brassica oleracea Nutrition 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 108010058651 thioglucosidase Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a preparation method of a broccoli extract and application thereof in preventing and treating leukopenia. The broccoli extract is obtained by carrying out enzymolysis on broccoli by using a broccoli endogenous enzyme system, then extracting and concentrating nutritional and health-care ingredients of the broccoli by using a solvent, and finally drying. The broccoli extract can be applied to the fields of food, health care products, medicines and the like to prevent and treat leukopenia.
Description
Technical Field
The invention relates to a preparation method of a broccoli extract and application thereof in preventing and treating leukopenia.
Background
In recent years, as the change in diet and living habits of people and the increase in pollution of the atmosphere, water quality, and the like have progressed, the incidence of leukopenia has been increasing, and attention has been paid to clinicians. There are many causes of leukopenia, including bacterial and viral infection, drug factors (such as chemotherapy drugs and antithyroid drugs such as propylthiouracil), connective tissue diseases (systemic lupus erythematosus, rheumatoid arthritis, sjogren's syndrome, etc.), digestive system diseases (liver cirrhosis, splenic hyperfunction, hepatitis, etc.), and blood system diseases (hematological malignancies, aplastic anemia, megaloblastic anemia, paroxysmal nocturnal hemoglobinuria, etc.). Among them, leukopenia is especially common in the course of tumor chemotherapy, and its main pathogenesis is due to lack of specificity of antitumor drug, while killing tumor cells, it also causes serious damage to normal cells, especially bone marrow hematopoietic cells with vigorous proliferation, resulting in decrease of blood cell number. The chemotherapy is often successfully carried out due to the secondary serious infection caused by the leucopenia, so that the clinical curative effect of the anti-tumor medicament is reduced, and the life quality of a patient is reduced. Therefore, the prevention and alleviation of bone marrow suppression after chemotherapy, the promotion of bone marrow hematopoietic function recovery and the increase of peripheral blood leukocytes become the key points for ensuring the successful completion of chemotherapy and improving the clinical curative effect of the antitumor drugs.
Broccoli (Brassica oleracea var. italia) mainly contains various nutritional ingredients such as protein, carbohydrate, fat, minerals, vitamin C and carotene. The nutritional ingredients are high in content and complete, wherein the content of vitamin C is about 20% higher than that of cauliflower belonging to the same Cruciferae, 2-3 times of that of cabbage and 5-6 times of that of tomato; the content of carotene is more than 30 times of that of cauliflower; the folic acid content is 2 times of that of cauliflower; the protein content is 3 times of that of cauliflower and 4 times of that of tomato. In addition, the mineral components in broccoli are more comprehensive than other vegetables, the contents of calcium, phosphorus, iron, potassium, zinc, manganese and the like are rich, and the broccoli is much higher than the cauliflowers of the same family and is known as a vegetable imperial crown. Broccoli has various physiological functions, and the anticancer effect of broccoli is an important content of research of scientists in western and japanese in recent years. The Japanese national cancer research center published anticancer vegetables on the leaderboard, the top of the name of broccoli. The research result that broccoli can effectively prevent the prostate cancer is also published in the journal of nutriology. Broccoli contains glucosinolates, which are hydrolyzed to sulforaphane under the catalysis of myrosinase, which is a key substance with anticancer effect in broccoli. Besides glucosinolates, broccoli also contains rich vitamin C, and can enhance the detoxification capability of the liver and improve the immunity of the organism; in addition, the product is rich in flavonoid substances, and has effects of preventing and regulating hypertension and heart disease. In addition, the broccoli belongs to high-fiber vegetables, and can effectively reduce the glucose absorption of intestines and stomach, further reduce the blood sugar and effectively control the illness state of the diabetic patients.
The broccoli related products have not been reported in the aspect of preventing and treating the leucopenia. The invention provides a preparation method of a broccoli extract and application of the broccoli extract in preventing and treating leukopenia.
Disclosure of Invention
The invention aims to provide a preparation method of a broccoli extract and application of the broccoli extract in preventing and treating leukopenia.
The broccoli extract can be used for preventing and treating leukopenia. Cyclophosphamide reduces leukocytes in animals primarily by DNA alkylation to disrupt DNA synthesis rather than specifically kill leukocytes. According to the invention, BALB/c mice are modeled by cyclophosphamide, then the number of white blood cells of BALB/c mice is detected by experiments, and the influence of cyclophosphamide (a model group), a stilbene gel leukocyte increasing capsule (a positive medicine), broccoli protein powder (sold in the market) and a broccoli extract prepared by the method on the number of white blood cells of the mice is examined. The experiment result shows that the broccoli extract has obvious effect of increasing the number of white blood cells of mice after the second molding, and the medicine effect is equivalent to that of the astragalus glue leucocyte increasing capsule with the same dosage. With the further reduction of the white blood cells, the broccoli extract group still had the efficacy of significant white blood cell increasing effect. The broccoli protein powder sold in the market at present has no related effect.
The invention also relates to a preparation method of the broccoli extract, which comprises the following steps:
(1) pulverizing at least one of stem, leaf and flower bulb of broccoli;
(2) carrying out enzymolysis on the crushed broccoli by an endogenous enzyme system;
(3) adding a solvent into the broccoli subjected to enzymolysis for extraction, and filtering to obtain a filtrate;
(4) drying the filtrate to obtain broccoli extract.
The enzymolysis conditions of the endogenous enzyme system in the step (2) are as follows: the time is 60 plus or minus 20 minutes; the temperature was 30. + -. 10 ℃.
The solvent in the step (3) is water, ethanol or a mixture of the water and the ethanol.
The drying method in the step (4) is vacuum concentration, freeze drying or spray drying and the like.
The following examples are further illustrative of the present invention but do not limit the invention.
Detailed Description
Example 1 preparation of broccoli extract 1
Crushing the whole broccoli by a crusher, placing 1kg of broccoli for 60 minutes at 30 ℃, adding 2 times of water, stirring for 30 minutes, filtering by gauze to obtain 1.0L of filtrate, and freeze-drying the filtrate to obtain 28g of broccoli extract 1.
Example 2 preparation of broccoli extract 2
Crushing 1kg of broccoli stems and leaves by a crusher, standing at 30 ℃ for 60 minutes, adding 2 times of water, stirring for 30 minutes, filtering by gauze to obtain 1.0L of filtrate, and freeze-drying the filtrate to obtain 25g of broccoli extract 2.
Example 3 preparation of broccoli extract 3
Crushing the whole broccoli by a crusher, taking 1kg, placing at 30 ℃ for 60 minutes, adding 2 times of ethanol, stirring for 30 minutes, filtering by gauze to obtain 1.0L of filtrate, and concentrating the filtrate in vacuum to obtain 30g of broccoli extract 3.
Example 4 Broccoli extract whitening experiment
BALB/c mice were modelled by cyclophosphamide to lower the number of leukocytes, and then the effect of the stilbene gel leukocyte increasing capsules, broccoli protein powder (Zhejiang river rice biotechnology, Ltd.) and broccoli extract prepared according to the present invention (examples 1 and 2) on the number of leukocytes in mice was examined.
(1) Molding die
50mg/kg cyclophosphamide is intraperitoneally injected once a day for 2 days continuously, and the model is made for 1 time per week and 3 weeks continuously. Normal group was injected with normal saline; the model group, the positive control group and the test object group are injected with cyclophosphamide in the abdominal cavity.
(2) Animal grouping and administration
BALB/c mice, SPF grade, supplied by the laboratory animal technology, Inc., Viton, Beijing, 72 BALB/c mice, 19-21g, males, were randomly divided into 6 groups of 12 mice each (see Table below).
TABLE 1 animal grouping and administration
| Group of | Dosage (mg/kg) | Volume of administration | Route of administration | Administration cycle |
| Normal control group | - | 20 | Gavage stomach | 21 days |
| Model set | - | 20 | Gavage stomach | 21 days |
| Capsule for raising white blood cell | 600 | 20 | Gavage stomach | 21 days |
| Broccoli protein powder | 600 | 20 | Gavage stomach | 21 days |
| Broccoli extract 1 | 600 | 20 | Gavage stomach | 21 days |
| Broccoli extract 2 | 600 | 20 | Gavage stomach | 21 days |
| Broccoli extract 3 | 600 | 20 | Gavage stomach | 21 days |
(3) Measurement of
On day 5 after the second week of modeling, the number of white blood cells in the tail vein blood of the mice was measured by a blood cell analyzer (mcdonax blood cell analyzer); on day 5 after the third week of modeling, the white blood cell count of the tail vein blood of the mice was measured by a blood cell analyzer.
(4) Statistical method
The data obtained from the experiments are all expressed as (MEAN + -SD), and the differences between groups are compared by using t-test.
(5) Results of the experiment
TABLE 2 influence of Broccoli extract on mouse leukocytes after second week molding (MEAN + -SD)
T test shows that the number of leucocytes of the model group mice after the second week modeling is obviously different from that of the normal group,###p<0.001, which indicates that the molding is successful; the number of white blood cells of mice in the astragalus membranaceus leucocyte increasing capsule, broccoli extracts 1, 2 and 3 was significantly different from that of the model group<0.01, which shows that the astragalus membranaceus leucocyte increasing capsule and the broccoli extracts 1, 2 and 3 can improve the leucocyte number of mice and have similar drug effects. There was no relevant effect of the broccoli protein powder.
TABLE 3 influence of Broccoli extract on mouse leukocytes after third week of modelling (MEAN + -SD)
T test shows that the number of leucocytes of the model group mice after the third week of modeling is obviously different from that of the normal group,###p<0.001, which indicates that the molding is successful;the number of white blood cells in mice in the broccoli extracts 1, 2 and 3 was significantly different from the model group<0.01，***p<0.001, which shows that broccoli extracts 1, 2 and 3 have the function of improving the number of leucocytes of mice with low immunity, the drug effect is superior to that of the astragalus glue leucocyte increasing capsule, and the broccoli protein powder has no related function.
Claims (7)
1. Use of broccoli extract for preventing and treating leukopenia is provided.
2. The broccoli extract according to claim 1, wherein at least one of the stem, leaf and curd of broccoli is pulverized and decomposed by its endogenous enzyme system.
3. The broccoli extract according to any one of claims 1 or 2, wherein the preparation method is characterized by comprising:
(1) pulverizing at least one of stem, leaf and flower bulb of broccoli;
(2) carrying out enzymolysis on the crushed broccoli by an endogenous enzyme system;
(3) adding water or aqueous solution with alcohol into the broccoli after enzymolysis, extracting and filtering to obtain filtrate;
(4) concentrating the filtrate under reduced pressure, and freeze drying or spray drying to obtain Broccoli extract.
4. The method for preparing broccoli extract according to claim 3, wherein the enzymolysis time of the endogenous enzyme system in step (2) is 60 ± 20 minutes.
5. The method for preparing broccoli extract according to claim 3, wherein the temperature for enzymolysis of the endogenous enzyme system in step (2) is 30 ± 10 ℃.
6. The method for preparing broccoli extract according to claim 3, wherein the alcohol in the step (3) is ethanol.
7. The broccoli extract according to claim 1, which is useful for food, health care products or pharmaceutical products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110433627.6A CN113134025A (en) | 2021-04-19 | 2021-04-19 | Application of broccoli extract in preventing and treating leukopenia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110433627.6A CN113134025A (en) | 2021-04-19 | 2021-04-19 | Application of broccoli extract in preventing and treating leukopenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113134025A true CN113134025A (en) | 2021-07-20 |
Family
ID=76813448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110433627.6A Pending CN113134025A (en) | 2021-04-19 | 2021-04-19 | Application of broccoli extract in preventing and treating leukopenia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113134025A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115227733A (en) * | 2022-07-22 | 2022-10-25 | 台州科技职业学院 | Application of broccoli extract in preventing and treating leukopenia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105524963A (en) * | 2016-01-28 | 2016-04-27 | 浙江省医学科学院 | Broccoli polypeptide extract as well as preparation method and application thereof |
| CN106135630A (en) * | 2015-04-10 | 2016-11-23 | 浙江海正药业股份有限公司 | A kind of preparation method and its usage of Caulis et Folium Brassicae capitatae egg albumen powder |
| CN106256250A (en) * | 2015-06-15 | 2016-12-28 | 浙江海正药业股份有限公司 | A kind of Caulis et Folium Brassicae capitatae hatches the preparation method of powder |
-
2021
- 2021-04-19 CN CN202110433627.6A patent/CN113134025A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106135630A (en) * | 2015-04-10 | 2016-11-23 | 浙江海正药业股份有限公司 | A kind of preparation method and its usage of Caulis et Folium Brassicae capitatae egg albumen powder |
| CN106256250A (en) * | 2015-06-15 | 2016-12-28 | 浙江海正药业股份有限公司 | A kind of Caulis et Folium Brassicae capitatae hatches the preparation method of powder |
| CN105524963A (en) * | 2016-01-28 | 2016-04-27 | 浙江省医学科学院 | Broccoli polypeptide extract as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| ZXBL龙: "针对白细胞减少的"食补方"", 《HTTP://WWW.360DOC.COM/CONTENT/18/0731/15/55687902_774675644.SHTML》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115227733A (en) * | 2022-07-22 | 2022-10-25 | 台州科技职业学院 | Application of broccoli extract in preventing and treating leukopenia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8927523B2 (en) | Compound sea cucumber preparation and manufacturing method thereof | |
| CN102153668B (en) | Anticancer Armillaria luteovirens polysaccharide and extraction process thereof | |
| CN103070880A (en) | Application of acanthopanax trifoliatus polysaccharide in preparing medicine for treating diabetes | |
| CN109939143A (en) | A kind of Chinese medicine composition and preparation method thereof for hypoglycemic control complication | |
| CN102349608A (en) | Healthcare product combination for clearing and nourishing throat and preparation method thereof | |
| CN108014150A (en) | Application of the natural drug composition in anti anoxia and radiation-resistant medicine or food is prepared | |
| Mathur et al. | Therapeutic use of wheat grass juice for the treatment of anemia in young women of Ajmer city (Rajasthan, India) | |
| CN106942578A (en) | A kind of natural meals for controlling purine intake and promoting uric acid excretion | |
| CN113134025A (en) | Application of broccoli extract in preventing and treating leukopenia | |
| CN107439787B (en) | Walnut oligopeptide with PM 2.5 particle resistance effect | |
| CN106421208B (en) | Pharmaceutical composition with chemical liver injury resistance function and preparation method thereof | |
| CN104940241B (en) | A kind of selenium worm grass compound preparation of prevention climacteric metancholia of women | |
| CN109589400B (en) | Composition with neuroprotective effect | |
| CN108570116B (en) | Pleurotus citrinopileatus polysaccharide, preparation method and medical application in preventing and treating diabetes | |
| CN109771457A (en) | Purposes of the russule extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease | |
| CN115227733A (en) | Application of broccoli extract in preventing and treating leukopenia | |
| CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
| CN103784492B (en) | Common pratia herb extract and its application with antitumor action | |
| CN107536016B (en) | A nutritional food for protecting heart and promoting liver health | |
| CN105287921A (en) | Medicinal composition for treating gastric cancer and preparation method thereof | |
| CN110404021A (en) | A kind of rhizoma polygonati preparation and preparation method | |
| CN109294984A (en) | A kind of Lentinan and preparation method thereof of internal efficient amplification NK cell | |
| CN107496485A (en) | The beneficial liver effect of pilose gerbera herb and application technology | |
| CN114159523B (en) | Application of dendrobium officinale in preparation of medicine for treating iron-deficiency anemia of women in childbearing age | |
| CN107496476A (en) | The beneficial liver effect of yunna cowparsnip and application technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210720 |
|
| WD01 | Invention patent application deemed withdrawn after publication |